The firm was founded under the 4:59 Initiative at 5AM Ventures and supported in its seed round by both 5AM Ventures and Binney Street Capital of the Dana-Farber Cancer Institute, where the company's technology was originally conceived. In parallel, Precede is internally developing blood-based clinical tests to detect cancer and guide therapeutic decisions in oncology. With the current research-use-only technology, the company aims to serve biopharma by identifying novel targets mechanistically linked to disease biology and measuring biological signals of response and resistance to treatment. Supported by $57 million in funding secured since its inception, Precede has developed a genome-wide methodology that analyzes circulating chromatin to measure both methylation and gene promotion using a 1-mL plasma sample. ![]() NEW YORK – Precede Biosciences on Thursday emerged from stealth mode to advance a blood-based platform that can detect the presence of cancer and other diseases and track dynamic changes in disease status in the context of treatment and other biological factors. ![]() Advances in Clinical Genomics Profiling.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |